Dihydropyrimidine Compounds and Their Uses in Preparation of Medicaments for Treating and Preventing Antiviral Diseases
申请人:Li Song
公开号:US20100087448A1
公开(公告)日:2010-04-08
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof, to a process for preparing the compound of formula (I), and to use of the compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof as a medicament, in particular as a medicament for the treatment and prevention of type B hepatitis.
[EN] CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS<br/>[FR] COMPOSÉS CARBOXY-BENZIMIDAZOLES MODULATEURS DU GLP-1R
申请人:GILEAD SCIENCES INC
公开号:WO2022225914A1
公开(公告)日:2022-10-27
The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
Selective Cyclooxygenase-2 Inhibitors: Heteroaryl Modified 1,2-Diarylimidazoles Are Potent, Orally Active Antiinflammatory Agents
作者:Ish K. Khanna、Yi Yu、Renee M. Huff、Richard M. Weier、Xiangdong Xu、Francis J. Koszyk、Paul W. Collins、J. Nita Cogburn、Peter C. Isakson、Carol M. Koboldt、Jaime L. Masferrer、William E. Perkins、Karen Seibert、Amy W. Veenhuizen、Jinhua Yuan、Dai-Chang Yang、Yan Y. Zhang
DOI:10.1021/jm0000719
日期:2000.8.1
A series of heteroaryl modified 1,2-diarylimidazoles has been synthesized and found to be potent and highly selective (1000-9000-fold) inhibitors of the human COX-2. 3-Pyridyl derived COX-2 selective inhibitor (25) exhibited excellent activity in acute (carrageenan induced paw edema, ED50 = 5.4 mg/kg) and chronic (adjuvant induced arthritis, ED50 = 0.25 mg/kg) models of inflammation. The relatively long half-life of 25 in rat and dog prompted investigation of the pyridyl and other heteroaromatic systems containing potential metabolic functionalities. A number of substituted pyridyl and thiazole containing compounds (e.g., 44, 46, 54, 76, and 78) demonstrated excellent oral activity in every efficacy model evaluated. Several orally active diarylimidazoles exhibited desirable pharmacokinetics profiles and showed no CI toxicity in the rat up to 100 mg/kg in both acute and chronic models. The paper describes facile and practical syntheses of the targeted diarylimidazoles. The structure-activity relationships and antiinflammatory properties of a series of diarylimidazoles are discussed.
DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USES IN PREPARATION OF MEDICAMENTS FOR TREATING AND PREVENTING ANTIVIRAL DISEASES
申请人:Beijing Molecule Science and Technology Co., Ltd.
公开号:EP2039686B1
公开(公告)日:2012-02-29
Sytschewa; Lebedewa, Zhurnal Obshchei Khimii, 1959, vol. 29, p. 1135,1138; engl. Ausg. S. 1106, 1108